What it's sold for

Mitochondrial function
Anti-aging
Energy
Muscle performance

What has actually been tested

Healthy Volunteers
Heart Failure
Age-related Macular Degeneration
Barth Syndrome
Healthy
Primary Mitochondrial Disease
Age Related Macular Degeneration (ARMD)
Age-Related Macular Degeneration

Is it studied for what it's sold for?

Each claim below is matched against the condition and title fields of every registered trial. Not listed means no trial names it as a studied condition — not that it has been disproven, and not that no trial touches it indirectly.

Studied Mitochondrial function

Not listed Anti-aging

Not listed Energy

Studied Muscle performance

Every trial on record

Every registered human study we can find for Elamipretide. Click any ID to read the original record — we would rather you checked us than trusted us.

Trial ID	Title	Condition	Phase	Status	Enrolled
NCT07531251	Clinical Trial in Patients With Barth Syndrome- 4TAZPower	Barth Syndrome	Phase 4	Recruiting now	48
NCT07275424	Study of Healthy Aging and Physical Function With Elamipretide	Aging, Healthy	Phase 2	Recruiting now	30
NCT05162768	Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)	Mitochondrial Myopathies, Mitochondrial Pathology	Phase 3	Completed	102
NCT01754818	A Phase 1 Study Examining the Pharmacokinetics and Tolerability of a Single Oral Dose of Bendavia (MTP-131)	Healthy	Phase 1	Completed	30
NCT02653391	A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)	Fuchs' Corneal Endothelial Dystrophy (FCED)	Phase 2	Completed	22
NCT02805790	Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study	Primary Mitochondrial Disease	Phase 2	Completed	30
NCT02693119	A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy	Leber's Hereditary Optic Neuropathy	Phase 2	Completed	12
NCT01572909	Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events	Reperfusion Injury, STEMI	Phase 2	Completed	300
NCT03891875	ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA	Age-related Macular Degeneration	Phase 2	Completed	176
NCT02436447	A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Function	Normal and Impaired Renal Function	Phase 1	Completed	23
NCT03098797	A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome	Barth Syndrome	Phase 3	Completed	12
NCT02848313	An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration	Age-Related Macular Degeneration	Phase 1	Completed	40
NCT02245620	A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly	Skeletal Muscle Mitochondrial Dysfunction in the Elderly	Phase 2	Completed	41
NCT05168774	FRDA Investigator Initiated Study (IIS) With Elamipretide	Friedreich Ataxia	Phase 2	Completed	20
NCT02388464	A Study Investigating the Safety, Tolerability, and Pharmacokinetics of MTP-131 in Subjects With Congestive Heart Failure	Congestive Heart Failure	Phase 1	Completed	36
NCT01115920	Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults	Healthy	Phase 1	Completed	40
NCT02788747	Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction	Heart Failure	Phase 2	Completed	71
NCT01513200	Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia	Healthy Volunteers	Phase 1	Completed	12
NCT02314299	A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration	Diabetic Macular Edema, Age-related Macular Degeneration	Phase 2	Completed	20
NCT02914665	A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure	Heart Failure	Phase 2	Completed	308
NCT01518985	The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking	Healthy Volunteers	Phase 1	Completed	6
NCT02367014	Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy	Mitochondrial Myopathy	Phase 2	Completed	36
NCT01786915	Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days	Healthy Volunteers	Phase 1	Completed	30
NCT02814097	A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction	Chronic Heart Failure	Phase 2	Completed	46
NCT02976038	Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)	Primary Mitochondrial Disease	Phase 2	Stopped early	28
NCT01755858	Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery	Renal Artery Obstruction, Hypertension, Renovascular	Phase 2	Stopped early	16
NCT02388529	A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia™ (MTP-131) in Patients With Heart Failure	Heart Failure	Phase 1	Withdrawn before enrolling	0 — nobody enrolled
NCT03323749	A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension	Primary Mitochondrial Myopathy	Phase 3	Stopped early	218
NCT06373731	ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)	Age Related Macular Degeneration (ARMD)	Phase 3	Running, closed to new participants	313

—Read this

A trial count is not a verdict

These numbers describe how much has been formally studied in humans, not whether something works or is safe for you. A compound can be tested for one condition and sold for another — which is usually the story. This page is automated aggregation from public registries; no physician has reviewed it. Take anything here to a clinician.

Why sources disagree on this number

Different sites publish different counts for Elamipretide because they are answering different questions. Here is every way of counting the same set of studies, so you can see which rule produces which number.

Registered human trials the number we publish

Interventional studies in people, listed on ClinicalTrials.gov, at any status.

Completed

Registered trials whose status is "completed".

Still running

Recruiting, not yet recruiting, or active.

Stopped early

Terminated, withdrawn, or suspended.

With a stated phase

Registered trials tagged Phase 1-4.

100+ participants

Registered trials enrolling at least 100 people.

Observational studies

Studies that watch rather than intervene.

You may see a lower number than 29.

Sources that count only completed studies get 22. We count registered trials at any status, because a trial that is recruiting is still a real trial and is the thing most likely to change this page. Neither number is wrong; they answer different questions.

Which number should you use?

For "how much human evidence exists", 29 is the honest answer, with the caveat that 22 have actually finished. Every trial is listed on this page with its ID — if you disagree with how we count, you can recount it yourself in about a minute.

Common questions about Elamipretide

How many human trials does Elamipretide have?

29. That is the number of registered interventional human studies we can find, each listed on this page with a link to its original record.

Is Elamipretide FDA approved?

Yes, but read the detail: FDA-approved (Forzinity, accelerated approval) to improve muscle strength in Barth syndrome, an ultra-rare mitochondrial disease. Approval does not extend to general anti-aging use. An approval for one condition is not an approval for everything it is marketed for.

What is Elamipretide actually being tested for?

Registered studies cover: barth syndrome, aging, healthy, mitochondrial myopathies. Compare that to what it is marketed for — the two lists are often different, which is the whole point of this page.

Where does this data come from?

ClinicalTrials.gov, the US public registry of clinical studies. We count interventional human studies only — observational studies are not evidence of effect. Every trial on this page links to its original record so you can check us rather than trust us.